Last reviewed 2026-04-22 · How we verify

Clarithromycin Syrup (125 mg)

Clarithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation and bacterial growth.

Clarithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation and bacterial growth. Used for Bacterial respiratory tract infections (community-acquired pneumonia, acute bronchitis), Otitis media, Sinusitis.

At a glance

Mechanism of action

Clarithromycin is a macrolide antibiotic that binds irreversibly to the bacterial 50S ribosomal subunit, blocking translocation of peptides and halting protein synthesis. This bacteriostatic action prevents bacterial replication and allows the immune system to clear the infection. It is effective against a broad spectrum of gram-positive and some gram-negative bacteria, as well as atypical organisms.

Approved indications

• Bacterial respiratory tract infections (community-acquired pneumonia, acute bronchitis)
• Otitis media
• Sinusitis
• Skin and soft tissue infections
• Helicobacter pylori eradication (as part of combination therapy)

Common side effects

• Diarrhea
• Nausea
• Abdominal pain
• Vomiting
• Headache
• QT prolongation
• Hepatotoxicity

Key clinical trials

• Acceptance of Clarithromycin in a Straw Compared to Syrup in Children With Upper Respiratory Tract Infections (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Clarithromycin Syrup (125 mg) CI brief — competitive landscape report
• Clarithromycin Syrup (125 mg) updates RSS · CI watch RSS
• Grünenthal GmbH portfolio CI